Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 13/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | GIPR | P48546 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1239632 | 0.88 | HDAC6 (0.39) | NR1H4PTGESALOX5HDAC11HDAC6 | |
| SCHEMBL1242713 | 0.83 | SERPINE1 (0.58) | SERPINE1NR1H4PTGESALOX5 | |
| SCHEMBL4010103 | 0.83 | SERPINE1 (0.48) | SERPINE1NR1H4PTGESALOX5HDAC11 | |
| SCHEMBL4441053 | 0.80 | NR1H4 (0.52) | SERPINE1NR1H4PTGESALOX5 | |
| SCHEMBL1242836 | 0.80 | SERPINE1 (0.58) | SERPINE1NR1H4PTGESALOX5 | |
| SCHEMBL4003060 | 0.80 | CCR9 (0.42) | SERPINE1NR1H4PTGESALOX5HDAC11 | |
| SCHEMBL1242259 | 0.79 | SERPINE1 (0.60) | SERPINE1NR1H4PTGESALOX5GLP1R | |
| SCHEMBL1241458 | 0.78 | PTGES (0.63) | SERPINE1NR1H4PTGESALOX5 | |
| SCHEMBL1242521 | 0.75 | PTGES (0.57) | SERPINE1NR1H4PTGESALOX5 | |
| SCHEMBL4005059 | 0.74 | NR1H4 (0.43) | SERPINE1NR1H4PTGESALOX5HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215899-A9 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-2072498-A1 | N-PHENYLOXAMIDIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-06-24 | — | — | EP | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249175-A1 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | SERPINE1 1/4885NR1H4 4184/4885PTGES 465/4885 |
| US-20090215899-A9 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | SERPINE1 1/4885NR1H4 4184/4885PTGES 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.